

**CURRICULUM VITAE**  
**Jill Bargonetti, Ph.D.**

**Current Positions:**

Hesselbach Professor of Biological Sciences  
Hunter College and The Graduate Center  
Adjunct Weill Cornell Medical College  
City University of New York  
413 East 69<sup>th</sup> Street Belfer Research Building  
New York NY 10021  
Phone: (212) 896-0465  
Email [bargonetti@genectr.hunter.cuny.edu](mailto:bargonetti@genectr.hunter.cuny.edu)

**HIGHER EDUCATION:**

<b><u>A. Degrees</u></b>	<b><u>Dates</u></b>	<b><u>Degrees</u></b>	<b><u>Date</u></b>
<b><u>Institution</u></b>	<b><u>Attended</u></b>	<b><u>and Major</u></b>	<b><u>Conferred</u></b>
New York University	1987-1990	Ph.D, Molecular Bio	10/90
New York University	1985-1987	M.S., Molecular Bio	6/87
SUNY College at Purchase	1980-1985	B.A., Biology	6/85

**B. Additional Higher Education**

<b><u>Institution</u></b>	<b><u>Dates Attended</u></b>	<b><u>Program</u></b>
Columbia University	1990-1994	Post-doctoral Fellow
Hunter College	Spring 2006	Interdisciplinary Research in Urban Public Health

**POSITIONS HELD AND EXPERIENCE:**

**AT CITY UNIVERSITY OF NEW YORK (CUNY) AT HUNTER COLLEGE (HC) and  
THE GRADUATE CENTER (GC) and WEILL CORNELL MEDICAL COLLEGE  
(WCMC):**

<b><u>Date</u></b>	<b><u>Rank</u></b>	<b><u>Department</u></b>
01/28/21-present	Hesselbach Professor	Biology (CUNY, HC)
08/01/23-present	Director <a href="http://www.NY-RaMP.org">www.NY-RaMP.org</a>	Multi at HC
01/01/07- present	Full Professor (tenured)	Biology (CUNY, HC & GC)
08/30/19-6/1/24	Chair MCD PhD Subprogram	Biology (CUNY, GC)
04/22/15-present	Adjunct Assistant Prof.	Weil Cornell (WCMC)
08/20/09-8/31/15	Chair MCD PhD Subprogram	Biology (CUNY, GC)
09/01/99 – 12/31/06	Associate Professor (tenured)	Biology (CUNY, HC & GC)
09/01/94 - 08/31/99	Assistant Professor	Biology (CUNY, HC & GC)
09/01/94-present	Doctoral Faculty: Biology and Biochemistry	(CUNY, GC)
01/28/94 - 03/18/94	Adjunct Assistant Professor	Biology (CUNY, HC)

**Teaching in Other Institutions**

<u>Institution</u>	<u>Dates</u>	<u>Rank</u>	<u>Department</u>
Columbia University	1992-1993	Supervised work-study student	Molecular Biology
Columbia University	Summer 1992	Mentor for minority internship student	Molecular Biology
New York University	1985-1986	Teaching Assistant	Biology

**Other (non-teaching)**

<u>Institution</u>	<u>Dates</u>	<u>Title</u>
Rockefeller University	2002	Visiting Associate Professor
Rockefeller University	1985	Research Technician
Institute of Rehabilitative Medicine, NYU Medical Center	1981	Summer Research Fellowship

**PROFESSIONAL SERVICE:**

2025- February, Basic Mechanisms in Cancer Health Disparities (BMCD) Study Section Ad Hoc Member

2024- October, Cancer Cell Biology Study Section Ad Hoc Member

2023- The National Institutes of Health Board of Scientific Counselors Ad Hoc Member

2022- present: Investigator Development Core Member: for the Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)

2021 April- present METAvivor Scientific Advisory Board Member

2017-present Program Steering Committee Member for NIH Funded UMass Boston-Dana Farber/Harvard Cancer Center U54 Partnership

2021-December ZRG OBT-M Member Conflict Cancer Genomics Study Section

2021-April ZRG1 OBT-K (02) Member Conflict Panel for Cancer Etiology and Cancer Genetics Study Section

2020-October Molecular Genetics B (MGB) study section NIH Ad Hoc Study Section Member

2020- June CAMP NIH Ad Hoc Study Section Member

2019-2020 Member ACS Peer Review Committee on Institutional Research Grants

2018-2020 Member AACR-AstraZeneca Stimulating Therapeutic Advances through Research Training (START) Grants Scientific Review Committee

2019 National Institutes of Health National Cancer Institute Site Visit Committee for the Laboratory of Cancer Biology and Genetics

2012-2018 Membership in The National Institutes of Health (NIH) Tumor Cell Biology Study Section Review Committee

2008 until 2011; Member NSF Proposal Panel Review Molecular and Cellular Biosciences. Gene Expression and Genome Dynamics; Signal Transduction.

2008: Cellular Signaling and Regulatory Systems (CSRS) NIH Study Section Reviewer

2006: NSF Post-doctoral Research Award Reviewer

2004: Department of Defense Breast Cancer Project, Member Molecular Genetics Study Section (2004)

2004: NIH Ad-Hoc Reviewer, NIH Minority Biomedical Research Support Program

2002 (for 3 years): National Cancer Policy Board Member of the National Academy of Sciences Institute of Medicine

2002: NIH CDF-1 Study Section Reviewer

2002-2013: NYU Graduate School Advisory Board

2000-2004: NSF Study Section Member: Signal Transduction and Cell Regulation

1999: Distinguished Review Committee for SUNY Purchase Liberal Arts and Sciences unit

1997-2008: PSC-CUNY Grant Application Review Committee

**ACADEMIC AND PROFESSIONAL HONORS:**

2023- Hunter College Elementary School Distinguished Alumni Award

2021-present Appointed to the Scientific Advisory Board of METAvivor. METAvivor is a non-profit organization dedicated to increasing awareness of advanced breast cancer and equity in research and patient support.

2021- present Preceptor for The Molecular and Translational Oncology Research (MTOR) NIH Funded T32 Training Program at Weill Cornell Medicine.

2021-present January 28<sup>th</sup> 2021 became the Marie L. Hesselbach Professor in Biological Sciences

2021 named to the 1000 Inspirational Black Scientists in America list: <https://crosstalk.cell.com/blog/1000-inspiring-black-scientists-in-america>

2020 New York Academy of Sciences Scientist-in-Residence for the 2020-2021 program year with placement at University Prep Charter High School for 12th grade AP Biology.

2017 Inducted into The Bronx High School of Science Hall of Fame

2014, Harvard University Recognition for Jocelyn Spragg Invited Lecture: "Celebrating Diversity in the Biomedical Sciences".

2011, American Association for Cancer Research Minority-Serving Institution Faculty Scholar in Cancer Research Award for the September (2011) International Conference on Frontiers in Basic Cancer Research.

2005, SUNY Purchase Presidential Distinguished Alumni/ae Award

2005, New York University Graduate School of Arts and Sciences: Distinguished Alumni/ae Award

2001, Outstanding Woman Scientist Award from the Association for Women in Science

2001, NYC Mayor's Award, Young Investigator Category from Rudolph Gulliani

1998, New York Voice Award: in recognition of individuals who have made a significant improvement to the quality of life in New York City

1998, CUNY Academy for the Humanities and Sciences Felix Gross Endowment Award Citation: For Outstanding Scholarly Achievement

1997, NAACP-New York Branch Kathy Keeton Mountain Top Award Citation: For Scholarly Excellence and a Life Long Commitment to the Struggle for Civil Rights

**1997, Presidential Early Career Award for Scientists and Engineers from William Clinton**

1996, Hunter Certificate of Appreciation for submitting a winning student paper in the Second Annual Paul LeClerc Library Research Paper Competition

1991, Honorable Mention Award-NSF Postdoctoral Fellowship for Minorities

1991, Damon Runyon-Walter Winchell Fellowship (three year duration)

1991, American Association of University Women Fellowship (declined)

1986, Honorable Mention- Ford Foundation Doctoral Fellowship for Minorities

1986, Honorable Mention- NSF Doctoral Fellowship for Minorities

1985, NYU Biology Department Teaching Assistant Award

1981, DeWitt Wallace Reader's Digest Fellow in Health Careers

### **EXTRAMURAL GRANT SUPPORT**

#### **Current Grants:**

**The Breast Cancer Research Foundation BCRF-24-011: Bargonetti, Jill (PI)**  
**\$225,000** October 1, 2024-September 30, 2025 “MDMX, MDM2, and Mutant p53 Signaling in Breast Cancer”. The study of signal transduction from the MDM2-MDMX axis in the context of mutant p53 that promotes aggressive and metastatic breast cancers.

PI: Bargonetti

**METAvivor Advisors Award: Bargonetti, Jill (PI) 6/1/2024-5/31/2026**

**\$200,000**

“Targeting Breast Cancer Metastasis by Combination Inhibition of CXCR4 and MDM2/MDM4” -Presented in honor of Caroline McIntyre and in memory of Sandy Gagliardi, members of Living with MBC Support Group in DENJPA

**NIH 5U54 CA 221704 TUFCCC/HC Partnership:**

**Pilot Project 10/1/2024 until 9/31/2027**

Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling.

Co-PIs Bargonetti and Connelly

**National Science Foundation 2318923**

**Total \$2,999,998.00 Project Period: 08/01/2023-07/31/2027-** RaMP-NY: Diversifying the National Biological Workforce through New York Transdisciplinary Bio Sciences (NY-RaMP).

PI: Bargonetti and Co-PIs: Kleiman and Wolfe

**NIH R01 CA239603-01A1:Project Period 2/06/2020-01/31/2025 Bargonetti, Jill (PI) \$389,255 PER YEAR: Total \$1,812,647:** “The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer”. Elucidating the role of the mutant p53-PARP-MCM signaling axis in the tumorigenesis and metastatic spread of triple negative breast cancer and leveraging this knowledge for the development of novel therapeutic strategies for the disease.

PI: Bargonetti

**NIMHD P50MD017341 (Terry, Shimbo, Williams, Phillips, Cohn, Hershman) 09/01/21 - 08/31/26 \$24,228,863**

**Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)**

The COMMUNITY Center of NYC brings together an interdisciplinary team of investigators, health care providers and community stakeholders around NYC through multi-institutional partnerships (Columbia, Hunter College, Cornell, New York Presbyterian Hospital, Physician Affiliate Group of New York) to reduce health disparities in multiple chronic diseases. We focus on cardiovascular disease and cancer, and their risk factors, as they are the two leading causes of death and that share common social context, etiological pathways, risk factors and management strategies.

**Previous Grants:**

**The Breast Cancer Research Foundation BCRF-24-011: Bargonetti, Jill (PI) \$225,000** October 1, 2023-September 30, 2024 “MDMX, MDM2, and Mutant p53 Signaling in Breast Cancer”. The study of signal transduction from the MDM2-MDMX axis in the context of mutant p53 that promotes aggressive and metastatic breast cancers.

PI: Bargonetti

**The Breast Cancer Research Foundation BCRF-23-011: Bargonetti, Jill (PI) \$225,000** October 1, 2023-September 30, 2024 “MDMX, MDM2, and Mutant p53 Signaling in Breast Cancer”. The study of signal transduction from the MDM2-MDMX axis in the context of mutant p53 that promotes aggressive and metastatic breast cancers.

PI: Bargonetti

**METAvisor Advisors Award: Bargonetti, Jill (PI) 6/1/2022-5/31/2024**

**\$200,000**

“Targeting Metastatic Breast Cancer Through the Mutant p53-PARP Axis”. The goals of the project are to determine if metronomic low dose administration of the PARP inhibitor talozoparib in combination with temozolomide can be effective to reduce triple negative breast cancer metastasis and improve lifespan.

**The Breast Cancer Research Foundation BCRF-22-011: Bargonetti, Jill (PI)**

**\$225,000** October 1, 2022-September 30, 2023 “MDMX, MDM2, and Mutant p53 Signaling in Breast Cancer”. The study of signal transduction from the MDM2-MDMX axis in the context of mutant p53 that promotes aggressive and metastatic breast cancers.

PI: Bargonetti

**NIH CTSC WCMC Pilot Sub-Award 7/1/2020-6/30/2022 Bargonetti, Jill (PI)**

**\$100,000**: “Pan-Cancer Organoid Models for Live Imaging Gain-of-Function Mutant p53”

PI: Bargonetti

**The Breast Cancer Research Foundation BCRF-21-011: Bargonetti, Jill (PI)**

**\$365,000** October 1, 2020-September 30, 2022 “MDMX, MDM2, and Mutant p53 Signaling in Breast Cancer”

PI: Bargonetti

**CUNY Fine Arts and Performing Arts Award:**

**\$2,500** 2019-2020 Academic Year “Exploring the Arts Through Choreographing Genomics”.

PI: Bargonetti

**Evelyn H. Lauder: The Breast Cancer Research Foundation:**

**\$250,000** per year October 1, 2018-September 30, 2020 “MDMX, MDM2, Mutant p53 Signaling in Breast Cancer”

PI: Bargonetti

**CUNY Fine Arts and Performing Arts Award:**

**\$2,500** 2017-2018 Academic Year “Exploring the Arts Through Choreographing Genomics”.

PI: Bargonetti

**NIH: CTBR Pilot Innovative Seed Funding Award** \$20,000 December 15, 2016- June 30, 2017 “The mutant p53-PARP-MCM Axis in Prostate Cancer”.

**NIH: CTSC** “Silencing components of the human injury transcriptome to minimize acute kidney injury” Co-PI: Bargonetti

**Evelyn H. Lauder: The Breast Cancer Research Foundation:**

\$250,000 PER YEAR October 1, 2015-September 30, 2018 "Estrogen Driven Mdm2 Signaling and Mutant p53 Signaling in Breast Cancer"

PI: Bargonetti

\$240,000 October 1, 2012-September 30, 2015 "Estrogen Driven Mdm2 Signaling and Mutant p53 Signaling in Breast Cancer"

**NIH (National Institutes in Health) CTBR Pilot Project Award:**

\$140,000 July 1, 2014-June 30, 2016 "MDM2 Oncogenic Functions Promoting Metastasis and Circulating Tumor Cells"

PI: Bargonetti

CoPI: Ogunwobi

**NIH (National Institutes in Health) RTRN Small Grants Program:**

\$50,000 July 1, 2014- June 30, 2015 "Evaluation of p53-MDM2 Oncogene Functions in Breast Cancer among Native Hawaiians"

PI: Loo

Mentor/Collaborator: Bargonetti

**NIH (National Institutes in Health) RCMI Pilot Award:**

\$170,000 July1, 2011- June 30, 2013 "Mdm2 and Mutant p53 Molecular Mechanisms of African American Breast Cancer Disparities"

**NIH (National Institutes of Health) Clinical Translational Science Center Pilot Award CTSC G12RR003037:**

\$100,000 June 1, 2011-May 31, 2013 "An Assessment of Mdm2C Isoform Protein as a Prognostic Factor in Breast Cancer"

**NIH (National Institutes of Health) Score 1SC1CA137843-01:**

\$844,000 direct costs (\$412,880 indirect. April 1, 2008-March 31, 2012 "p53-Independent Cell Death Signaling by Mitomycin DNA Adducts." 1SC1CA137843

**NSF Grant Application 0744316:**

\$480,000, May 1 2008- April 30, 2012

Growth Control Regulated by p53 and Mdm2 on Chromatin MCB 0744316

**Evelyn H. Lauder: The Breast Cancer Research Foundation:**

\$223,000 October 1, 2010-September 31, 2012 " Activation of p53-Independent and p53-Dependent Cell Death Pathways in Estrogen Influenced Breast Cancer Cells"

From 2005-2010 was "Estrogen Influences on the p53 Checkpoint in Breast Cells".  
\$200,000 per year for 5 years.

**CUNY Research Equipment Grant:** \$40,000 March 12, 2007



“Acquisition of Becton-Dickinson’s FACSCalibur 4-Color Benchtop Flow Cytometer”

**NSF (National Science Foundation): MCB-0212761;** \$315,000 September 1, 2002-August 31, 2006. “Growth Control Regulated by p53 and Mdm2.”

**CUNY Research Equipment Grant:** \$36,667 February 13, 2004  
“A Benchtop FACS Analyzer for Hunter College”

**NIH (National Institutes of Health) Score: 1S06 GM60754;** \$340,000 (direct) April 1, 2000-March 31, 2004 “Mitomycin C Signaling to and from p53 During the Cell Cycle.”

**NIH (National Institutes of Health):** \$64,000 (direct), July 1, 2001-December 31, 2003. “Mitogenic signaling through Ral A and Phospholipase D.”

**NSF Early Career Award:** MCB-9722262, \$507,125, September 1, 1997 - August 31, 2002. “Growth Control Regulated by p53 and mdm2.”

**DOD (Department of Defense):** \$60,000, September 1, 1997 - August 30, 2000. pre-doctoral award for Maria Patricia Molina, a Ph.D. student working in Dr. Bargonetti’s lab. “Patterns of proteins that associate with p53 or with p53 binding sites present in the Ribosomal Gene Cluster and mdm2(p2) promoter”.

**NIH:** HHS-L/C: 5G12RR03037-11, \$154,000 (direct), July 1, 1995 - June 30, 1998. RCMI Supplement for an AIDS related project. “Wild-type and Mutant p53 Interactions with HIV-LTR DNA”.

**American Cancer Society:** CN-140 AM. CHEM., \$300,000, July 1, 1995 - June 30, 1998. “In vivo Occupancy of p53 Binding Sites During Cell-Cycle.

**U.S. Army:** DAMD 17-94-J-4030, \$200,000, June 30, 1994 - July 1, 1998. “The In Vivo DNA Binding Properties of Wild-type and Mutant p53” Proteins in Mammary Cell Lines during the Course of Cell-Cycle. Career Development Award: 4 year duration

**PUBLICATIONS:** (present-1991)

Lee R, Ellison V, Forbes D, Gao C, Katanov D, Kern A, Levine F, Leybengrub P, Ogunwobi O, Xiao G, Feng Z, **Bargonetti J.** Chemokine CXCL12 Activates CXCR4 Receptor 4 Metastasis Signaling Through the Upregulation of a CXCL12/CXCR4/MDMX (MDM4) Axis. *Cancers (Basel)*. 2024 Dec 16;16(24):4194. doi: 10.3390/cancers16244194. PMID: 39766093.

Ellison V, Polotskaia A, Xiao G, Leybengrub P, Qiu W, Lee R, Hendrickson R, Hu W, **Bargonetti J.** A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO

CHROMATIN. bioRxiv [Preprint]. 2024 Jan 23:2024.01.20.576487. doi: 10.1101/2024.01.20.576487. PMID: 38328189; PMCID: PMC10849484.

Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, **Bargonetti J**. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. *Cancer Lett.* 2024 Jan 9;584:216608. doi: 10.1016/j.canlet.2024.216608. Epub ahead of print. PMID: 38199587.

Wang J, Chang CY, Yang X, Zhou F, Liu J, **Bargonetti J**, Zhang L, Xie P, Feng Z, Hu W. p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome. *Nat Commun.* 2024 Jan 2;15(1):137. doi: 10.1038/s41467-023-44390-w. PMID: 38167344; PMCID: PMC10762193.

Lundine D, Annor GK, Chavez V, Maimos S, Syed Z, Jiang S, Ellison V, **Bargonetti J**. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose. *Mol Cancer Res.* 2022 Dec 2;20(12):1799-1810. doi: 10.1158/1541-7786.MCR-22-0133. PMID: 36074101. **WE GOT THE COVER!**

Canar J, Manandhar-Sasaki P, **Bargonetti J**. Mutant *C. elegans* p53 Together with Gain-of-Function GLP-1/Notch Decreases UVC-Damage-Induced Germline Cell Death but Increases PARP Inhibitor-Induced Germline Cell Death. *Cancers (Basel).* 2022 Oct 8;14(19):4929. doi: 10.3390/cancers14194929. PMID: 36230851; PMCID: PMC9563635.

Lama R, Xu C, Galster SL, Querol-García J, Portwood S, Mavis CK, Ruiz FM, Martin D, Wu J, Giorgi MC, **Bargonetti J**, Wang ES, Hernandez-Ilizaliturri FJ, Koudelka GB, Chemler SR, Muñoz IG, Wang X. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. *Front Oncol.* 2022 Aug 5;12:933446. doi: 10.3389/fonc.2022.933446. PMID: 35992795; PMCID: PMC9389462.

Annor GK, Elshabassy N, Lundine D, Conde DG, Xiao G, Ellison V, **Bargonetti J**. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. *Front Cell Dev Biol.* 2021 Nov 22;9:772315. doi: 10.3389/fcell.2021.772315. PMID: 34881245; PMCID: PMC8645790.

Wilson, T. Pirovano, G., Xiao, G., Samuels, Z., Roberts, S., Viray, T., Guru, N., Zanzonico, P., Gollub, M., Reiner, T., and **Bargonetti, J.**, PARP Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. *ACS Molecular Pharmaceutics* 2021 July 28 online first PMID: 34318678.

Ellison, V., Annor, G.K., Freedman, C., Xiao, G., Lundine, D., Freulich, E., Prives C., and **Bargonetti, J.**, Frame-shift Mediated Reduction of Gain-of-function p53 R273H and Deletion of the R273H C-terminus in Breast Cancer Cells Result in Replication-Stress Sensitivity. *Oncotarget* 2021 June 8: 12 (12):1128-1146 PMID: 34136083

**Bargonetti, Jill.** "How Choreostorming Informs Thinking In Molecular Genetics And Cancer Biology" *Leonardo* MIT Press March 11, 2021 doi: 10.1162/LEON\_a\_02053

Xiao, G., Annor, G K., Fung, K., Keinänen, O., Zeglis, B.M. and **Bargonetti J.** Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. *ACS Molecular Pharmaceutics* 2021 Jan 4;18(1):338-346. EPub Dec 2020 PMID: 33289569

Kim, J.Y., Lee, R. Xiao, G., Forbes, D., and **Bargonetti, J.** MDM2-C is an E3 Ubiquitin Ligase. *Cancer Management and Research* 2020 August Volume:12 Pages 7715—7724 PMID: 32904724

Farooqi, K., Ghazvini, M., Pride, L.D., Mazella, L., White, D., Pramanik, A., **Bargonetti, J.** and Wood Moore, C. A Protein in the Yeast *Saccharomyces cerevisiae* Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. *Biomolecules* 2020 Mar 7;10(3):417.doi: 10.3390/biom10030417.

Xiao, G., Lundine, D., Annor, G.K., Canar, J., Ellison, V., Polotskaia, A., Donabedian, P., Reiner, T., Khramtsova, G.K., Olopade, O., Mazo, A., and **Bargonetti, J.** Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. *Cancer Research* 2020 Feb 1;80(3):394-405. doi: 10.1158/0008-5472. PMID: 31776133

Gao, C., Xiao, G., and **J. Bargonetti.** Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. *Oncotarget* 2019 Aug 20;10(49):5007-5010. PMID: 31489110

**Bargonetti, J.**, and C. Prives. Gain of function mutant p53: history and speculation. *Journal of Molecular and Cellular Biology* 2019 Jul 19;11(7):605-609. PMID: 31283823

Gao, C., Xiao, G. Piersigilli, A., Gou, J. Ogunwobi, O. and **Bargonetti, J.** Context Dependent Roles of MDMX (MDM4) and MDM2 in Breast Cancer Proliferation and Circulating Tumor Cells. *Breast Cancer Research*, 2019 Jan 14;21(1):5. doi: 10.1186/s13058-018-1094-8. PMID: 30642351

Loo, L.W.M., Hernandez, B. Y., Shvetsov, Y., Okoro, D. R., Gao, C. and **Bargonetti, J.** MDM2, MDM2-C, and Mutant p53, Expression Influence Breast Cancer Survival in a Multiethnic Population, *Breast Cancer Research and Treatment* 2019 Feb;174(1):257-269. doi: 10.1007/s10549-018-5065-7. EPub November 23, 2018. PMID: 30470976

Kundu, N., Brekman, A., Kim, J. Y., Xiao, G., Gao, C., and **Bargonetti, J.** Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway, *Oncotarget* 2017 Jul 18;8(29):47916-47930. doi: 10.18632/oncotarget.18147 PMID: 28615518

Qiu WG, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson RC, and **Bargonetti J.** Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. *NPJ Breast Cancer* 2017 Feb; 3. pii: 1. doi: 10.1038/s41523-016-0001-7 PMID: 28232952

Shtraizent N, Matsui H, Polotskaia A, and **Bargonetti J.** Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. *Int J Environ Res Public Health.* 2015 Dec 22;13(1) . pii: E22. doi: 10.3390/ijerph13010022. PMID: 2670366

Rosso M, Polotskaia A, and **Bargonetti J.** Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. *Oncotarget.* 2015 Oct 27;6(33):34573-91. doi: 10.18632/oncotarget.5312. PMID: 26416444

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, **Bargonetti J,** Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C. Mutant p53 cooperates with SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. *Genes Dev.* 2015 Jun 15;29(12):1298-315. doi: 10.1101/gad.263202.115. Epub 2015 Jun 16. PMID: 26080815

Polotskaia, A., Xiao, G., Reynoso, K., Hendrickson, R., Martin, C., Qiu, W. and **J. Bargonetti.** Proteome-wide Analysis of Mutant p53 Targets in Breast Cancer Identifies New Levels of Gain-of-Function that Influence PARP, PCNA and MCM4. (2015) *Proc Natl Acad Sci U S A.* Mar 17;112(11):E1220-9. doi: 10.1073/pnas.1416318112. Epub 2015 Mar 2. PMID: 25733866

Xiao, G., Kue, P., Bhosle and **J. Bargonetti.** Decarbamoyl Mitomycin C (DMC) Activates p53-independent Ataxia Telangiectasia and Rad3 Related Protein (ATR) Chromatin Eviction. (2015) *Cell Cycle* Epub ahead of print Jan 7. PMID: 25565400

Rosso, M., Okoro, D, and **Bargonetti, J.** Splice Variants of MDM2 in Oncogenesis. *Subcell Biochem.* (2014) 85, 247-61. PMID: 25201199

Shi, M., Shtraizent, N., Polotskaia, A., **Bargonetti, J.** H. Matsui. Impedimetric Detection of Mutant p53 Biomarker-Driven Metastatic Breast Cancers under Hyposmotic Pressure. (2014) *PLoS One* Jan 7;9(6):e99351 PMID: 24937470

Hoffman S., Martin, D., Melendez A. and **J. Bargonetti** C. *elegans* p53 and Beclin 1 are involved in DNA repair. (2014) *PloS One Feb 20;9(2):e88828*. PMID: 24586407

Okoro D., Arva N., Gao, C., Polotskaia A., Puente, C., Rosso, M., and **J. Bargonetti**. Endogenous Human MDM2-C is Highly Expressed in Human Cancers and Functions as a p53-independent Growth Activator. (2013) *PloS One Oct 11;8(10):e77643*. PMID: 24147044

Catalina-Rodriguez, O., Preet, A., Kolukula, V., Furth, P., Albanese, C, **Bargonetti, J.** and M.L. Avantiaggiati. Dietary regulation of p53 mutant levels influences tumorigenesis. (2012) *Cell Cycle 11(23):4436-46* PMID:23151455

Polotskaia, A., Hoffman, S., Krett, N., Shanmugam, M., Rosen, S., and **Bargonetti J.** 8-Aminoadenosine activates p53-independent cell death of metastatic breast cancers. (2012) *Molecular Cancer Therapeutics 11(11):2495-504* PMID:22973058

Okoro D., Rosso M., and **J. Bargonetti**. Splicing up Mdm2 for Cancer Proteome Diversity. *Genes & Cancer 2012. Invited Review 3(3-4):311-9* PMID:23150764

"Success in Molecular Genetics: The Pink Flower" in *Voices of Black American Pioneers*, edited by Vernon Farmer, Greenwood Publishing Group, Westport, Connecticut (Invited Book Chapter 2012).

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerod, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., Bissell, M. J., Osborne, T. F., Tian, B., Lowe, S. W., Silva, J. M., Borrensen-Dale, A.-L., J., L. A., **Bargonetti, J.**, and Prives, C. (2012) Mutant p53 Disrupts Mammary Acinar Morphogenesis via the Mevalonate Pathway, *Cell 148* (1-2): 244-58 PMID: 22265415

Brekman, A., Singh K.E., Polotskaia A., Kundu N. and **Bargonetti J.** A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. (2011) *Breast Cancer Res. 13* (1):R3: PMID: 31333569

Boamah, E.K., Brekman, A., Tomasz, M., Myeku, N., Figueiredo-Pereira, M., Hunter, S., Meyer, J. Bhosle, R.C. and **Bargonetti, J.** DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of Checkpoint Protein 1. (2010) *Chem. Res. Toxicol. 19* (23): 1151-62 PMID: 20536192

**Bargonetti, J.**, Champeil E. and Tomasz, M. Differential Toxicity of DNA Adducts of Mitomycin C. (2010) *Invited Review Journal of Nucleic Acids*. Jul 29;2010. pii: 698960: PMID: 698960

Paz, M.M., Ladwa, S., Champell, E., Liu, Y., Rockwell, S. Boamah, E.K., **Bargonetti, J.**, Callahan, J., Roach, J., and Tomasz, M. Mapping DNA Adducts of Mitomycin and Decarbamoyl Mitomycin C in cell Lines Using Liquid Chromatography/ Electrospray Tandem Mass Spectrometry. (2008) *Chem. Res. Toxicol.*, **21**(12): 2370-2378.

Arva, N., Talbott, K., Okoro, D., Brekman, A., Qiu, W., and **Bargonetti, J.** Disruption of the p53-Mdm2 Complex by Nutlin-3 Reveals Different Cancer Cell Phenotypes. (2008) *Ethnicity and Disease*, 18(2 Suppl 2):S2-1-8.

Boamah, E., White, D., Talbott, K., Arva, N., Berman, D., Tomasz, M., and **Bargonetti, J.** (2007) Mitomycin-DNA Adducts Induce p53-Dependent and p53-Independent Cell Death Pathways. *ACS Chemical Biology* 2(6): 399-407.

Hui, L., Zheng, Y., Yan, Y., **Bargonetti, J.**, and D. Foster (2006). Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. *Oncogene* 25(55): 7305-10.

White, D.E., Talbott, K.E., Arva, N.C. and **J. Bargonetti.** (2006). Mdm2 Associates with Chromatin in the Presence of p53 and is Released to Facilitate Activation of Transcription. *Cancer Research* 66(7): 3463-70.

Arva, N.C. , Gopen, T.R., Talbott, K.E., Campbell, L.E., Chicas, A., White, D.E., Bond, G., Levine, A. and J. Bargonetti (2005). A chromatin associated and transcriptionally inactive p53-mdm2 complex occurs in mdm2 SNP309 homozygous cells. *J. Biol. Chem.* 280(29):26776-87

Bond, G.L., W. Hu, E.E. Bond, H. Robins, F. Bartel, H. Taubert, P. Wuerl, K. Onel, L. Yip, S. Hwang, L.C. Strong, N.C. Arva, **J. Bargonetti**, G. Lozano, and A.J. Levine. (2004). A Single Nucleotide Polymorphism in the Mdm2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. *Cell* 119:591-602.

Hui, L., Abbas, T., **Bargonetti, J.**, and D.A. Foster. (2004). Phospholipase D Elevates the Level of MDM2 and Suppresses DNA Damage-Induced Increases in p53. *Mol. Cell Biology* (24): 5677-5686.

Abbas, T., D. White, L.Hui, .D.A., Foster and **J. Bargonetti.** (2004). Inhibition of p53 transcription by down-regulation of protein kinase C delta. *Journal of Biological Chemistry* 279 (11):9970-9977.

Molina, M. P., C. Cain, and **J. Bargonetti** (2003). In Vivo footprinting and DNA Affinity Chromatography for Analysis of p53 DNA Binding Ability. *Methods in Molecular Biology* 234:151-70.

Abbas, T., M. Olivier, J. Lopez,, S. Houser, G. Xiao, G. S. Kumar, M. Tomasz, and **J. Bargonetti** (2002). Differential activation of p53 by the various adducts of Mitomycin C. *Journal of Biological Chemistry* 277(43):40513-9.

**Bargonetti, J.** and J.J. Manfredi. (2002). Multiple roles of the tumor suppressor p53. *Curr. Opin. Oncology*. 14:86-91.

Houser, S., S.Koshlatyi , T. Lu , T. Gopen, and **J. Bargonetti** (2001). Camptothecin and Zeocin Can Differentially Increase p53 Levels During all Cell Cycle Stages. *Biochem Biophys Res Commun*. 289:998-1009.

Chicas, A., P. Molina, and **J. Bargonetti** (2000). Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. *Biochem Biophys Res Commun*. 279:383-390.

Xiao, G., A. Chicas, M. Olivier, Y. Taya, S. Tyagi, F.R. Kramer and **J. Bargonetti**, (2000). p53 requires a damage signal to activate gadd45. *Cancer Research* 60: 1711-1719.

Boydston-White, S., T. Gopen, S. Houser, **J. Bargonetti** and M. Diem, (1999). Infrared spectroscopy of human tissue: V. Infrared Spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. *Biospectroscopy* 5: 219-227.

Xiao, G., D. White, and **J. Bargonetti** (1998). p53 binds to a constitutively nucleosome free region of the mdm2 gene. *Oncogene* 16:1171-1181.

**Bargonetti, J.**, A. Chicas, D. White, and C. Prives (1997). p53 represses Sp1 DNA Binding and HIV-LTR directed transcription. *Cellular & Molecular Biology* 43:935-949.

Chen, X., J. Bargonetti, and C. Prives, (1995). p53, through p 21 (WAF1/CIP1), induces cyclin D1 synthesis. *Cancer Research* 55:4257-4263.

Prives, C., J. Bargonetti, G. Farmer, E. Ferrari, P. Friedlander, U. Hubsher, L. Jayaraman, N. Pavletich, and Y. Wang, (1994). The DNA binding properties of the p53 tumor suppressor protein. *CSHS on Quan. Bio*. LIX:207-213.

Bargonetti, J., J.J. Manfredi, X. Chen, D.R. Marshak, and C. Prives, (1993). A proteolytic fragment from the central region of p53 has marked sequence-specific binding activity when generated from wild-type but not from oncogenic mutant p53 protein. *Genes and Dev*. 7:2565-2574.

Bargonetti, J., P.Z. Wang, and R.P. Novick, (1993). Measurement of gene expression by translational coupling: effect of copy mutations on pT181 initiator synthesis. *EMBO* 12:3659-3667.

Friedman, P.N., X. Chen, J. Bargonetti, and C. Prives, (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA. *Proc. Natl. Acad. Sci. USA.* 90:3319-3323.

Bargonetti, J., I. Reynisdottir, P.N. Friedman, and C. Prives, (1992). Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. *Genes and Dev.* 6:1886-1898.

Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives, (1992). Wild-type p53 activates transcription in vitro. *Nature* 358:83-86.

Zambetti, G.P., J. Bargonetti, K. Walker, C. Prives, and A.J. Levine, (1992). Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. *Genes and Dev.* 6:1143-1152.

Bargonetti, J., P.N. Friedman, S.E. Kern, B. Vogelstein, and C. Prives, (1991). Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. *Cell* 65:1083-1091.

Prives, C., J. Bargonetti, P.N. Friedman, J.J. Manfredi, and E.H. Wang, (1991). Functional consequences of the interactions of the p53 tumor suppressor protein and SV40 large tumor antigen. *CSHS on Quan. Bio.* LVL:227-235.

**Contributor for National Cancer Policy Board Reports: Member 2002-2005**

Fulfilling the Potential of Cancer Prevention and Early Detection *National Cancer Policy Board* (March 10, 2003)

Describing Death in America *National Cancer Policy Board* (April 3, 2003)

Large Scale Biomedical Science: Exploring Strategies for Future Research *National Cancer Policy Board* (June 19, 2003)

Improving Palliative Care: We Can Take Better care of People With Cancer *National Cancer Policy Board* (August 19, 2003)

Childhood Cancer Survivorship: Improving Care and Quality of Life *National Cancer Policy Board* (August 26, 2003)

**PROFESSIONAL ACTIVITIES:**

**Invited Speaker:**



April 2025  
Gordon Research Conference  
DNA Replication Gaps, Cancer and Disease  
Daejeon, South Korea

January 21<sup>st</sup> 2025  
The Wistar Institute, Philadelphia PA  
Distinguished Lecture in Cancer Research  
Targeting the Mutant p53-PARP-MCM Axis in Triple Negative Breast Cancer

January 17<sup>th</sup> 2025  
Institutional Research and Career Developmental Award (IRACDA) Symposium  
Keynote Speaker, SUNY Stony Brook, NY  
Choreographed Mentoring for Inclusion and Creativity Development in Science

November 8<sup>th</sup> 2024  
Brooklyn College Cancer Center, NY  
Targeting Breast Cancer by Inhibition of the Mutant p53-PARP Cancer Persistent  
Repair Axis

November 1<sup>st</sup> 2024  
Empire State Development Symposium, NY NY  
Innovating for Inclusion: Building a Diversified Precision Medicine Workforce –  
Perspectives from a Cancer Genetic Counselor and a Breast Cancer  
Researcher.

October 28<sup>th</sup> 2023  
SUNY Purchase, NY  
Breast Cancer Biomarkers  
MDM2 and p53 are Important Biomarker

October 16<sup>th</sup> 2023  
10<sup>th</sup> MDM2 International Workshop, Osaka, Japan  
MDM2 and MDMX Signaling in Breast Cancer Metastasis and DNA Damage  
Repair

October 4<sup>th</sup> 2023  
New York Area Genome Integrity Discussion Group  
The MDM2-MDMX-Mutant p53 Axis in Breast Cancer Has Impact on 53BP1-  
MDC1 Chromatin Recruitment.

September 2022  
*AACR: Minorities in Cancer Research Professional Advancement Session*

Developing Strategic Partnerships in Research

June 2022

*The Pink Agenda: Breast Cancer Awareness*

PCR or Rapid: MDM2 and p53 are Important Biomarkers

April 2022

*University of Massachusetts Boston*

“Dissecting the gain-of function mutant p53 pathway and its relationship to PARP-mediated DNA repair” and “Blending One’s Creative and Scientific Interests.”

March 2022

*The University of Texas at Arlington*

Dissecting the gain-of function mutant p53 pathway and its relationship to PARP-mediated DNA repair.

March 11, 2022

*Gordon Research Conference on DNA Damage, Mutation, and Cancer*

“Exploring the interface between the mtp53-PARP axis and DNA replication regulation.”

October 19<sup>th</sup> 2021

*University of Puerto Rico Rio Piedras Campus*

“Exploring cancer biology through the lens of targeting the mutant p53 pathway.”

September 29<sup>th</sup> 2021

*University of Buffalo*

“How One Black Woman in a White Science World Got Tenure and Found Herself in the Process”

August 11, 2021

*New York Academy of Sciences*

*Cultivating STEM Identity*

June 28<sup>th</sup> 2021

*Inclusive Research and Teaching for a Diverse Nation-National Conference*

“Choreostorming our Understanding of Cancer Biology.”

June 22<sup>nd</sup> 2021

*ASM Microbe Keynote*

“A Black woman in a White world escapes the underfunded microbiology research enterprise.”

April 2021: Choreostorming: Using Choreography of Cancer Genomics to Expand Art and Science Blending  
Purchase College Alumni Weekend

April 2021: Panelist for "Women, who Lead STEM" webinar at the Borough of Manhattan Community College

February 2021: Panel Member Speaker for The Estée Lauder Companies Network of Black Leaders and Executives Work Cancer Day Webinar on Breast Cancer in the Black Community Panel Discussion

June 24<sup>th</sup> 2020  
AACR Virtual Annual Meeting II  
Targeting gain-of-function of mutant p53 C-terminal and oligomerization domains  
Disrupt activated DNA replication in breast cancer

June 23<sup>rd</sup> 2020  
Converge to Transform Webinar:Hacking Biology to Advance Medicine  
Targeting the Oncogenic Mutant p53 Protein to Detect and Treat Triple Negative Breast Cancer

May 4<sup>th</sup> 2020  
Brown University  
The Molecular Choreography of Mutant p53 and MDM2 in Breast Cancer

April 17<sup>th</sup> 2020  
Hunter College Black Student Union  
COVID-19/SAR-CoV-2 Facts and Fiction

February 6<sup>th</sup> 2020  
Honoring Bronx High School of Science Seniors in Research  
The Science of Treating Cancers by Targeting Mutant p53  
<https://thesciencesurvey.com/hall-of-fame-alumni/2020/04/14/science-research-celebration-2020/>

November 4<sup>th</sup> 2019  
Tulane School of Medicine  
The Molecular Choreography of Mutant p53 and MDM2 in Breast Cancer

June 6<sup>th</sup> 2019  
Estee Lauder Breast Cancer Campaign  
Panel Speaker at the Employee Engagement Campaign

February 21<sup>st</sup> 2019  
Columbia University Women in Science and Students of Color Alliance

Being a Black Woman in Science

January 23<sup>rd</sup> 2019

University of Chicago Medical School

The Molecular Choreography of Mutant p53 and MDM2 in Breast Cancer

November 14<sup>th</sup> 2018

Panel Speaker at the BCRF Westchester Hot Pink Luncheon

November 4<sup>th</sup>-7<sup>th</sup> 2018: MDM2 International Workshop Tampa Florida

Context Dependent Roles of Mutant p53 MDMX (MDM4), and MDM2.

September 2018: St. John's University Biology Department Seminar Series

The Molecular Choreography of Mutant p53 and MDM2 in Breast Cancer

April 2018: Women In Stem: Youngstown University

Keynote Speaker

The Molecular Choreography of Mutant p53 and MDM2 in Breast Cancer

March 2018 NYC Science and Engineering Fair Keynote Speaker

A Cancer Biology Career

March 2018: 2<sup>nd</sup> Annual Belfer Symposium

Triple Negative Breast Cancer: New Targets

December 2017: SciArt Center

Art & Science: The Two Cultures Converging

<https://www.sciartcenter.org/conference-roundtables-2017.html>

STEAM Roundtable #2

April 2017: Coldwell University

*Keynote Speaker for Research and Arts Day*

Choreographing Genomics and Cancer Biology into Understanding

January 2017: Belfer Symposium

Identification, Validation, and Targeting of the Mutant p53-PARP Chromatin Axis  
in Triple Negative Breast Cancer

November, 2016

American Association for Cancer Research

DNA Repair: Tumor Development and Therapeutic Response

November 2016

St. John's University

Identification, Validation, and Targeting of the Mutant p53-PARP Chromatin Axis  
in Triple Negative Breast Cancer

October 2016  
CUNY Graduate Center  
Future Initiative  
Enacting a Different Stem

October 2016  
Oncology Support Program HealthAlliance Speaker  
Choreographing Cancer Biology

*October 2016: The Metropolitan Association of College and University Biologists*  
**Keynote Speaker**  
Unraveling the Creativity of Choreographing Cancer Genomics

*June 2016: NYC BioBus*  
*Dance of The Cancer Cell*  
April 2016  
Keynote Speaker  
State University of New York Undergraduate Research Conference  
“p53 and MDM2 in Cancer Research”.

March 2016: Weill Cornell Medical College Cell Biology Seminar  
“Mutant p53 and MDM2 Signaling in Breast Cancer”

February 2016: Roswell Park Cancer Institute  
“Mutant p53 and MDM2 Signaling in Breast Cancer”

December 2015: CUNY TEDx  
“Choreographing Genomics”

November 2015: University of Pittsburgh Medical Center  
“Mutant p53 and MDM2 Signaling in Breast Cancer”

November 2015: International MDM2 Workshop in New Orleans  
“A p53-independent Role of MDM2 in Breast Cancer”

September 2015: SUNY Bridges Key Note Speaker  
“Unraveling Creativity for Scientific Inquiry”

January 2015: New York Medical College  
“MDM2 and Mutant p53 Signaling in Breast Cancer”

December 2014: Fordham University

“Splicing up *mdm2* for cancer proteome diversity”

June 2014: The Cancer Institute of New Jersey

“MDM2 and Mutant p53 Signaling in Breast Cancer”

May 2014: Harvard Division of Medical Sciences

The Jocelyn Spragg Lecture

“MDM2 and Mutant p53 Signaling in Breast Cancer”

January 2014: University of Hawaii Cancer Center

“MDM2 and Mutant p53 Signaling in Breast Cancer”

April 2013: National Institutes of Health Diversity Working Group

“Increasing Scientific Workforce Diversity:

Broader Impact Assessment Measurements to Ensure Benefits to Society”

February 2012: Columbia University PRIDE Scholar Speaker

“Developing and Maintaining Networks”

November 2011: Brooklyn College “Canonical versus Non-canonical Functions of p53 and Mdm2 in Breast Cancer”

October 2011: International Mdm2 Workshop

“The non-canonical pathway of highly expressed Mdm2-C protein in human cancer cell lines and liposarcomas”

October 2010: Women’s Leadership Conference: Invited Panel Speaker (CUNY);

“Breaking Boundaries in Science and Health: New Careers and Challenges”.

September 2010: Women and Science Forum: Invited Panel Speaker (CUNY

Graduate Center); “Inspiring Women Scientists”.

February 2010: Montana State University “Pharmacogenomics for Cancers with Compromised p53”.

October 2009: Albert Einstein School of Medicine “Pharmacogenomics for Cancers with Compromised p53”.

January 2009: 22<sup>nd</sup> Annual International Symposium of the Hunter College Gene Center “Pharmacogenomics for Cancers with Compromised p53”.

November 2008: ABRCMS Meeting “Targeting DNA-Adduct Stereochemistry and p53-Mdm2 Complexes for Improved Breast Cancer Cell Death”.

March 2008: Hunter College Wisterians Alumni Tenth Black Scholars Lecture  
"Regulation of Transcription And How It Relates to Cancer Development"

February 2008, Northwestern University Comprehensive Cancer Center

October 2008 International Mdm2 meeting

2007 Minority Graduate Student Minority Event at Albert Einstein

2006 NYU Embracing Diversity Meeting

February 2007, Brooklyn College

November 2006, University of Rochester

November 2006, Queens College, CUNY

October 2006, New York University

November 2005, Abbott Distinguished Lectureship, Purdue University

October 2005, City College, CUNY

April 2005, SUNY Purchase Annual Bridges Lecture

February 2005, SUNY Health Science Brooklyn

March 2004, NIH National Institute on Aging Monthly Seminar Series

January 2004, NSF CAREER Meeting: Senior Mentor-Speaker

October 2004, Hofstra: Graduate Student Seminar Series

May 2003, Cold Spring Harbor: Protein Phosphorylation and Cell Signaling

2002, The Harvard Club "Breakfast with a Scientist"

2002, "Women in Science" Keynote Speaker for CUNY Science Conference

2001, Distinguished Visiting Professor Lecture at Indiana University at  
Bloomington

2000, 16<sup>th</sup> Annual Oncogene Meeting the SALK (talk)

- 2000, LIJ Medical Center for Grand Rounds
- 1998, Public Health Research Institute, NYC
- 1998, Rockefeller University Apoptosis Club
- 1998, PSC-CUNY Tribute to Betty Shabaz
- 1998, Hunter High School Career Day Symposium
- 1998, "A Salute to Excellence in Public Education" by Controller Hevesi
- 1998, Hunter College Library Day Celebration
- 1998, "The Urban University: Pathways to Careers in Biomedical Science for Minority Scientists and Engineers."
- 1997, SUNY Purchase Science Alumni Symposium
- 1997, Black History Month Celebration at Prince of Peace Lutheran Church
- August 1996, CSHL Cancer Genetics & Tumor Suppressor Genes, "The relationship of p53 to chromatin remodeling of the mdm2 gene".
- May 16, 1995, PHRI, Invited Seminar Speaker, "p53 binds to the HIV-LTR and represses transcription".
- April 28, 1995, Hunter College, RCMI Symposium on Apoptosis. Symposium Speaker, "The relationship between p53 transcriptional repression and apoptosis".
- 1992, CSHS Molecular Biology of SV40, Polyoma, and Adenovirus CSH, NY.

**Poster Presentations and Abstracts:**

**November 2024 ABRCS:** Examining the Functional Relationship between the Amino Acids in Mutant p53 C-terminal Domain, Poly-ADP-Ribose and Poly-ADP-Ribose Polymerase1. Valery Chavez, Valerie Vasquez, Dilsanely Minaya, Meghan Scott, Anna Boers, Dr. Devon Lundine, Dr. George K. Annor, Dr. Gu Xiao, Dr. Viola Ellison and Dr. Jill Bargonetti

**August 13<sup>th</sup>-17<sup>th</sup> Cold Spring Harbor Meeting: Mechanisms and Models of Cancer.** A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin.



Viola Ellison, Gu Xiao, Alla Polotskaia, Pamela Leybengrub, Rusia Lee, Nikita Meghani, Weigang Qiu, Ronald Hendrickson, Wenwei Hu, Jill Bargonetti

**September 19<sup>th</sup> 2023 Cold Spring Harbor Meeting: Biology of Cancer: Microenvironment and Metastasis.** MDM4 (MDMX) in Mutant p53 Expressing Breast Cancer Cells Activates the CXCL12-CXCL4 Metastasis Cytokine Signaling Axis. Rusia Lee, Dominique Forbes, Pam Leybengrub, Alexandra Kern, Viola Ellison, Gu Xiao, Chong Gao, Olorunseun Ogunwobi, and Jill Bargonetti

**September 19<sup>th</sup> 2023 Cold Spring Harbor Meeting: Biology of Cancer: Microenvironment and Metastasis.** The Mutant p53 C-terminus Promotes Breast Cancer Circulating Tumor Cells and Metastasis that Can be Targeted by Synergistic PARPi Talazoparib plus Temozolomide Treatment. Gu Xiao<sup>1</sup>, George Annor, Valery Chavez, Fayola Levine, Katherine Harmon, Olorunseun Ogunwobi and Jill Bargonetti

**September 5<sup>th</sup> 2023 Cold Spring Harbor Meeting: DNA Replication and Genome Maintenance.** Missense Mutant p53 C-terminal Amino Acids Interact with Poly-ADP-Ribose, Replicating DNA, and Promote Xenograft Breast Cancer Tumors in NSG Mice. Presented by **Valery Chavez**, George Annor, Valerie Vasquez, Gu Xiao, Fayola Levine and Jill Bargonetti

**September 5<sup>th</sup> 2023 Cold Spring Harbor Meeting: DNA Replication and Genome Maintenance.** A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 to chromatin. Presented by **Viola Ellison**, Alla Polotskaia, Gu Xiao, Pamela Leybengrub, Weigang Qiu, Jill Bargonetti, Hunter College, The Department of Biological Sciences, Belfer Research Building, New York, NY,

#### **April 2023 AACR Annual Meeting**

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Presented by **Madorsky Rowdo F**, Khramtsova F, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Adinku MO, Aitpillah FS, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter P, Hoda S, Newman L, Elemento O, Olopade O, Davis MB, Martin ML, and Bargonetti J.

**November 9<sup>th</sup> 2022 Annual Biomedical Research Conference for Minoritized Scientists (ABRCMS) 2022.** Presented by **Dominique Forbes**. Exogenous Purified MDMX Addition to Triple Negative Breast Cancer Cell Extracts Promotes Increased Cellular Protein Ubiquitination. Dominique Forbes, Rusia Lee, and Jill Bargonetti

**November 7<sup>th</sup> 2022 7<sup>th</sup> US-EU Conference on Endogenous DNA Damage and Repair.** *Examining the Functional Interactions of Mutant p53 C-terminus and PARP1 that Promote DNA Replication.* Presented by Valery Chavez  
Valery Chavez, Devon Lundine, George Annor, Gu Xiao, Viola Ellison and Jill Bargonetti

**April 12<sup>th</sup> 2022 AACR Annual Meeting in NOLA**  
Identification of MDMX/MDM2 Signaling Pathways in Breast Cancer Cells with Mutant p53. Presented by Rusia Lee  
Rusia Lee, Viola Ellison, Gu Xiao, Dominique Forbes, Pam Leybengrub, Alexandra Kern, Falande Alexandre, George Annor, Jill Bargonetti

**December 2021 San Antonio Breast Cancer Conference**  
Tetrameric and Monomeric Gain-of-Function Mutant p53 Interacts with Chromatin.  
G.K. Annor, N. Elshabassy, D. Lundine, D.G. Conde, V. Ellison, and J. Bargonetti

**August 2020 CSHL Models and Mechanisms of Cancer**  
Targeting the oligomerization domain of gain-of-function mtp53 R273H to disrupt chromatin-based activities  
G. Annor, C. Freedman, V. Elison, G. Xiao, Devon Lundine and J. Bargonetti

**The PARP Family and ADP-Ribosylation CSHL 2018**

Gain-of-Function Mutant p53 R273H interacts with DNA replication for fork in association with PARP.  
Gu Xiao, Alla Polotskaia, Patrick Donabedian, Thomas Reiner and Jill Bargonetti

**Annual AACR 2018**

MDM2 and MDMX promote p53-independent initiation of circulating tumor cells from triple negative breast cancer.  
Chong Gao, Gu Xiao, Alessandra Piersigilli, Jiangtao Gou, Olosunseun Ogunwobi and Jill Bargonetti

**The 17<sup>th</sup> International p53 Workshop July 2017 Biopolis Singapore**

Identification, Validation, and Targeting of the Mutant p53-PARP-MCM Chromatin Axis in Hormone Insensitive Prostate and Breast Cancer.  
Wei-Gang Qiu, Alla Polotskaia, Gu Xiao, Devon Lundine, Lia Di, Yuhan Zhao, Wenwei Hu, John Philip, Ronald Hendrickson and Jill Bargonetti

**Annual AACR 2017**

Identification of the mutant p53-PARP-MCM chromatin axis as a triple negative breast cancer replication stress target.

Wei-Gang Qiu, Alla Polotskaia, Gu Xiao, Lia Di, Zhao, Y., Hu, W, John Philip, Ronald Hendrickson and Jill Bargonetti

The association between p53, MDM2, and MDM2 isoform C protein expression and survival in a multiethnic population of breast cancer patients.

Loo, L. W., Hernandez, B. Y., Shvetsov, Y., Okoro, D., Gao, C., and Jill Bargonetti

### **The 17<sup>th</sup> International p53 2017**

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis hormone insensitive prostate and breast cancer.

Jill Bargonetti, Alla Polotskaia, Gu Xiao, Lia Di, Devon Lundine, Yuhan Zhao, Wenwei Hu, John Philip, Ronald Hendrickson, and Wei-Gang Qiu

### **Annual AACR 2016**

Proteome-wide Triple Negative Breast Cancer Mutant p53 Association Index Identifies Chromatin Unwinding for Precision Therapeutics.

Wei-Gang Qiu, Alla Polotskaia, Gu Xiao, Lia Di, John Philip, Ronald Hendrickson and Jill Bargonetti

### **Annual AACR 2015**

Proteome-wide Analysis of Gain-of-Function Mutant p53 Targets in Breast Cancer Implicates PARP, PCNA and MCM4 as Oncogenic Drivers. Alla Polotskaia, Gu Xiao, Katherine Reynoso, Che Martin, Wei-Gang Qiu, Ronald Hendrickson and Jill Bargonetti

MDM2 promotes p53-independent breast cancer metastatic phenotypes  
Chong Gao, Nandini Kundu, and Jill Bargonetti

### **Cold Spring Harbor Laboratories: Mechanisms and Models of Cancer 2014**

Mutant p53 in Breast Cancer Induces Proteome Changes in Cholesterol Biosynthesis Enzymes, PARP and PCNA. Polotskaia, A., Xiao, G., Reynoso, K., Hendrickson, R., Martin, C., Qui, W. and J. Bargonetti.

A p53-independent Function of MDM2 is Required for Estrogen-Mediated Breast Cancer Proliferation and this Disrupts 3D Mammary Architecture. Nandini Kundu, Katherine Reynoso, and Jill Bargonetti

**Annual AACR 2014**

Cancer cells with G/G *mdm2* SNP309 have compromised transcriptional elongation of p53 target genes. Melissa Rosso, Alla Polotskaia and Jill Bargonetti

Real-time impedance analysis of triple negative breast cancer cells from African Americans demonstrates oncogenic mutant p53 (mtp53) is a promoter of cellular deformability. Shtraizent N., Shi M., Polotskaia A., Matsui H. and Bargonetti J.

**Annual AACR 2013**

Multiple Mdm2 isoforms promote tumorigenesis, disrupt mammary tissue architecture, and are endogenously expressed in cancers. Danielle Okoro, Nandini Kundu, Chong Gao, Cindy Puente, Alla Polotskaia, Nicoleta Arva, Melissa Rosso and Jill Bargonetti

**Maui Frontiers AACR 2013**

Mdm2 Splice Variant Protein Products Promote Tumorigenesis, Disrupt Mammary Tissue Architecture, and Are Endogenously Expressed in Cancers. Danielle Okoro, Nandini Kundu, Chong Gao, Cindy Puente, Alla Polotskaia, Nicoleta Arva, Melissa Rosso and Jill Bargonetti

**CSHL Epigenetics Meeting 2012**

Inhibition of Transcriptional Elongation at p53 Target Genes in Cancer Cells with *mdm2* SNP 309. Melissa Rosso, Alla Polotskaia, Jill Bargonetti.

**August 2012: CSHL Mechanisms & Models of Cancer**

Human Mdm2-C is Highly Expressed in Certain Cancers and Donates a Non-canonical Function. Danielle Okoro, Chong Gao, Cindy Puente, Alla Polotskaia, Nicoleta Arva, and Jill Bargonetti.

**April 2012: AACR Annual Meeting**

Non-canonical functions of Mdm2 isoforms in estrogen influenced breast cancer cells with wild-type and mutant p53. Jill Bargonetti, Danielle Okoro, Nandini Kundu, Angelika Brekman, Chong Gao, Melissa Rosso and Alla Polotskaia

**October 2011: Sixth International Mdm2 Workshop**

Mdm2 in G/G SNP309 MANCA cells is up-regulated by p53 but *p21* and *puma* are inhibited following transcription initiation. Melissa Rosso, Alla Polotskaia and Jill Bargonetti.

The Non-canonical Pathway of Highly Expressed Mdm2-C Protein in Human Cancer Cell Lines and Liposarcomas. Danielle Okoro, Melissa Rosso, Cindy Puente, Alla Polotskaia, Nandini Kundu, Nicoleta Arva and Jill Bargonetti.

**September 2011: AACR Frontiers in Basic Cancer Research**

p53 Independent 8-amino-adenosine Mediated Breast Cancer Cell Death. Alla Polotskaia and Jill Bargonetti.

**December 2010 RCMI Bridging the Gap between Disparity and Equity**

Estrogen-mediated proliferation of breast cancer cells requires Mdm2 to bypass the G1 checkpoint. Angelika Brekman, Kathryn E. Talbott, Alla Polotskaia and Jill Bargonetti.

**May 2010 CSHL Cell Cycle Meeting:**

Estrogen-mediated proliferation of breast cancer cells requires Mdm2 to bypass the G1 checkpoint. Angelika Brekman, Kathryn E. Talbott, Alla Polotskaia and Jill Bargonetti.

An Hdm2 isoform, Hdm2C, promotes cell proliferation without decreasing p53. Danielle Okoro, Melissa Rosso, Cindy Puente and Jill Bargonetti.

**April 2010 AACR Annual Meeting:**

Mdm2 and oncogenic mutant p53 as biomarkers for potential drug targets in estrogen receptor positive and triple negative breast cancer. Alla Polotskaia, Angelika Brekman, Jill Bargonetti

**February 2010 AACR Cell Death Meeting:**

Is *C. elegans* a versatile pre-clinical chemotherapeutic testing model for p53-independent cell death pathways? Sandy Gamss, Ryan Doonan, Alicia Meléndez and Jill Bargonetti

**June 2009 C. elegans meeting University of California:**

Chemotherapeutic activation of CEP-1-dependent and CEP-1-independent Cell Death in *Caenorhabditis elegans*. Sandy Gamms, Alicia Melendez, Jill Bargonetti.

**April 2009 AACR Annual :**

Pharmacogenomics for cancers with compromised p53 by mdm2 SNP309 or mutations in the p53 gene. Alla Polotskaia, Angelika Brekman, Sandy Gamms, Alicia Melendez, Jill Bargonetti.

The N2-deoxyguanosine adducts of mitomycins with mitosene-1-B stereochemistry efficiently kill cells with compromised p53 through proteasome-mediated degradation of Chk1. Ernest Boamah, Angelika Brekman, Maria Tomasz, Natura Myeku, Maria Figueredo-Pereira, Jill Bargonetti.

**December 2008 SanAntonio Breast Cancer Meeting:**

p53 Transcriptional Activity is Selectively Suppressed by Estrogen in SNP309 Mdm2 Overexpressing Breast Cancer Cells. Angelika Brekman, Kathryn E. Talbott and Jill Bargonetti

**August 2008 Cold Spring Harbor Mechanism and Models of Cancer:**

Increased  $\beta$  DNA Adducts are Associated with Downregulation of Chk1 During p53- Dependent AND p53- Independent Cell Death. Ernest Boamah<sup>1</sup>, Angelika Brekman<sup>1</sup>, John Roach<sup>2</sup>, John Callahan<sup>2</sup>, Maria Tomasz<sup>1</sup>, and Jill Bargonetti<sup>1</sup>.

p53 Transcriptional Activity is Selectively Suppressed by Estrogen in SNP309 Mdm2 Overexpressing Breast Cancer Cells. Angelika Brekman, Kathryn E. Talbott and Jill Bargonetti

**July 2008, Cancer Models and Mechanism Gordon Conference:**

Targeting DNA-Adduct Stereochemistry and p53-Mdm2 Complexes for Improved Cancer Cell Death. Presenter: Jill Bargonetti

Characterizing mdm2 alternative spliced variants induced from the internal second promoter. Danielle Okoro, Nicole Arva, PhD, Cindy Puente, Kathryn Talbott and Jill Bargonetti, PhD

CEP-1/p53-independent Cell Death in *Caenorhabditis elegans*. Sandy Gamss, Alicia Meléndez and Jill Bargonetti

**October 2007, IV International Mdm2 Meeting:**

Alternative splicing of human *mdm2* in SNP 309 homozygous cells produces transcripts with potential to encode Mdm2 proteins with altered function. Danielle Okoro, Nicole Arva, Cindy Puente, Kathryn Talbott and Jill Bargonetti, PhD

Roles of Mdm2 and Estrogen Receptor in Resistance to p53-Dependent and p53-Independent Breast Cancer Cell Death. Angelika Brekman, Kathryn E. Talbott, and Jill Bargonetti.

**April 2007, Keystone Apoptotic and Non-Apoptotic Cell Death Pathways Meeting, Monterey, CA: 2 Posters**

Mdm2 Isoforms and p53-Mdm2 Chromatin Complex Disruption in Cancer Cell Death. Nicoleta Arva, Kathryn Talbott, Angelika Brekman, Danielle Okoro and Jill Bargonetti

Differential Signaling by Stereoisomeric Mitomycin-DNA Adducts Activates Alternative p53 Dependent and Independent Cell Death Pathways. Ernest Boamah, David White, Kathryn Talbott, Maria Tomasz, and Jill Bargonetti.

**December 2006, Tenth International RCMI Symposium, Puerto Rico: 2 Posters**

p53-Mdm2 chromatin complex disruption in cell death and growth arrest in cancer cells with over-expressed Mdm2. Nicoleta Arva, Kathryn Talbott, Angelika Brekman, Danielle Okoro, and Jill Bargonetti

Differential Signaling by Stereoisomeric Mitomycin-DNA Adducts Activates Alternative p53 Dependent and Independent Cell Death Pathways. Ernest Boamah, David White, Kathryn Talbott, Maria Tomasz, and Jill Bargonetti.

**May 2006, International p53 Conference, Columbia University, New York City: 2 Posters**

The potential of Nutlins to release chromatin-bound Mdm2 and activate p53 in cells with *mdm2* SNP309 or amplified genotypes. Nicoleta C. Arva, Kathryn Talbott, and Jill Bargonetti.

Mitomycin C and its derivative 10-decarbamoyl mitomycin C activate alternate cell death pathways. Ernest K. Boamah, David E. White, Kathryn E. Talbott, Nicoleta C. Arva, Dan Berman, Tarek Abbas, Maria Tomasz, and Jill Bargonetti.

**June 2005, Cold Spring Harbor Symposium LXX: Molecular Approaches to Controlling Cancer: 2 Posters**

A novel mitomycin DNA-adduct provokes alternative caspase p53-dependent and p53-independent apoptotic pathways. David E. White, T. Abbas, K.E. Talbott, D. Berman, E. Boamah, S. Simpson, N.C. Arva, M. Tomasz, and J. Bargonetti.

A chromatin associated and transcriptionally inactive p53-mdm2 complex occurs in mdm2 SNP309 homozygous cells. Arva, N.C., Gopen, T.R., Talbott, K.E., Campbell, L.E., Chicas, A., White, D.E., Bond, G., Levine, A. and J. Bargonetti

**Einstein in the city: City College CUNY: 2 Posters**

*Transcriptional Inactivation of DNA Bound p53 in Cell Lines Homozygous for the Mdm2 309 SNP.* Nicoleta Arva, and Jill Bargonetti.

*A Novel Mitomycin DNA-Adduct Provokes Alternative Caspase p53-dependent and p53 Independent Apoptotic Pathways.* Ernest Boamah, David E. White, N.C. Arva, T. Abbas, K.E. Talbott, M. Tomasz, and J. Bargonetti.

**August 2004, Cold Spring Harbor: Cancer Genetics and Tumor Suppressor Genes. 3 Posters**

*Transcriptional Inactivation of DNA Bound p53 in Cell Lines Homozygous for the Mdm2 309 SNP.* Nicoleta Arva, T. Gopen, L. Campbell, K. Talbott, D. White, G. Bond, A. Levine and J. Bargonetti.

*A Novel Mitomycin DNA-Adduct Provokes Alternative Caspase p53-dependent and p53 Independent Apoptotic Pathways.* David E. White, N.C. Arva, T. Abbas, K.E. Talbott, M. Tomasz, and J. Bargonetti.

*Repression of mdm2 Transcription by the Topoisomerase Inhibitor camptothecin occurs in the presence of Chromatin Associated p53 Complexes reduced in MDM2 Association.* David, E. White, K. Talbott, and J. Bargonetti.



June 2003 International Meeting on Angiogenesis in Cancer  
*Inhibition of p53 Basal Transcription by TPA Treatment and Down-regulation of PKC delta.* Tarek Abbas, David White, Li Hui, David A. Foster, and Jill Bargonetti

May 2003, Cold Spring Harbor: Protein Phosphorylation and Cell Signaling: *Inhibition of p53 Basal Transcription by TPA Treatment and Down-regulation of PKC delta.* Tarek Abbas, David White, Li Hui, David A. Foster, and Jill Bargonetti

October 2003, Second International Mdm2 workshop: 2 Posters

*Cells With an Impaired DNA Damage Response Have Inactivation of Wild Type p53 Through a p53-Hdm2-Nucleolin Complex.* Tamara Gopen, T. Lu, S. Koshlatyi, D. White and J. Bargonetti.

*Differential regulation of p53 Responsive Genes May be Controlled by Hdm2.* David White, T. Gopen, T. Abbas, and J. Bargonetti.

Many Student Posters not recorded for 1999-2000 at the following annual meetings:

Oncogene meetings, AACR meetings and CSHS.

1999, CSHS Molecular Biology: Cancer Genetics and Tumor Suppressor Genes

1998, CSHS Molecular Biology: Cancer Genetics and Tumor Suppressor Genes

1997, CSHS Mechanisms of Eukaryotic Transcription

1997, Gordon Research Conference: CANCER

1996, Gordon Research Conference: CANCER

1995, Gordon Research Conference: CANCER

1992, Cold Spring Harbor Advanced Molecular Cloning Course

1992, Eighth Annual Meeting on Oncogenes, Frederick Maryland

1992, UCLA Symposia on Molecular and Cellular Biology 21st Annual Meetings

Keystone, Colorado

## **INVOLVEMENT IN PLANNING NATIONAL AND INTERNATIONAL SCIENTIFIC MEETINGS:**

January 2009

22<sup>nd</sup> Annual International Symposium on Translational Cancer Research

National Center for Research Resources (NCRR) and National Institutes of Health (NIH)

New York, New York

Chair

May 2006

13<sup>th</sup> Annual International p53 Workshop at Columbia University  
Columbia University  
New York, New York  
Co-organizer

January 2005  
19<sup>th</sup> Annual International Symposium: Minorities, Race, Genomics and Health Iniquities:  
What are the connections?  
National Center for Research Resources (NCRR) and National Institutes of Health (NIH)  
New York, New York  
Chair

**Editorial Work:**

PLoS Genetics; Oncogene; PNAS; EMBO; JBC; MCB; FASEB; PLoS Biology,  
Molecular Cancer Therapeutics

**SUPPLEMENTAL CREDENTIALS:**

**Patents:**

Provisional Patent :630233306 "Detecting and treating cancers using cell penetrant  
mtp53-oligomerization-domain peptide" 5-26-2020, Jill Bargonetti-Chavarria, Gu Xiao,  
Brian Zeglis, George Annor, and Kimberly Fung.

Patent number:688771 "Method of characterization of biological entities" May 3, 2005  
Max Diem, S. Boydston-White, J. Bargonetti and T. Gopen

Provisional Patent, Reg.# 33,529 "A system and method to Determine Absence or  
Presence of Cancerous Disease by Infrared Spectroscopy", 1-22-99; approved, issue  
data Feb 2005, Max Diem, S. Boydston-White, J. Bargonetti and T. Gopen

**Performance Art:**

Art and Science: The Two Cultures Converging  
December 1-3, 2017  
<http://www.sciartinitiative.org/conference-roundtables-2017.html>  
Steam and the future of education: Choreographing Genomics

Thinkathon: a day-long laboratory investigating research methods and practices/an  
experiment in thought and action  
April 16, 2011  
12-8pm Riese Student Lounge, Tisch School of the Arts

721 Broadway (corner of Broadway and Waverly)

www.centerforcreativeresearch.org

Participants include: Jill Bargonetti, Barbara Browning, Una Chaudhuri, Emily Coates, Lacina Coulibaly, Jennifer Homans, Hana Iverson, Natalie Jeremijenko, Ralph Lemon, Liz Lerman, Cassie Meador, Bebe Miller, Eiko Otake, Dana Reitz, Mike Shelley, Elizabeth Streb, Angela Zito, Ellen Zweig, and NYU graduate students: Biba Bell, Nicole Daunic, Annie Friedensen, Abigail Levine, Marina Libel, and others.

**MEMBERSHIP IN PROFESSIONAL SOCIETIES:**

2021-Present	Fellow of the New York Academy of Medicine/
2006-Present	Member American Association for Cancer Research
2005-Present	Professional Member of the New York Academy of Sciences
2003-Present	Member American Society for Biochemistry and Molecular Biology
1996-Present	Full Member Sigma Xi Research Society
1992-Present	Member American Association for the Advancement of Science

**ADMINISTRATIVE AND OTHER SERVICE ON BEHALF OF THE DEPARTMENT AND COLLEGE:**

**Departmental Committees:**

Department Personnel & Budget Committee 2001-2020  
Graduate Advisory Committee: Biology/Biochemistry PhD Advisor 2001-present  
Space Committee 1999-2002

**School of Arts & Sciences Committees:**

**2020-COVID-19** Hunter College Research Restart Committee  
**MARC/MBRS** Graduate Affairs & Recruiting Committee  
**SCORE** Steering Committee Group Leader  
**NIH/SCORE** Advisory Committee  
**RCMI** Biopreparation, Recruiting and Symposium Committees (years 1994, 1995, 2005 Chair for 20<sup>th</sup> Anniversary Symposium: 12/9/2005, 2009, Chair of Cancer Symposium

**College Committees:**

Faculty Delegate Assembly  
Middle States Research Task Force  
Summer - College Association  
Nominating Committee for Senate Sub. Committees  
Graduate Seminar Series Committee  
Graduate Student Affairs and Recruitment

**Ph.D. Program Advisory Committee Membership:**

Graduate Advisory Committee Chair 2009-present  
Graduate Advisory Committee Member 2008-present

NAME: Jill Bargonetti

36

Graduate Deputy Chair, Biology Program 2001-2002  
PSC/CUNY Grant Reviewer, 1995 to present  
Special Committee to review basic course requirements

36

**Student Laboratory Supervision and Mentor**

**Ph.D. Students -** George Annor- Ph.D. degree 9/2022  
Nicoleta Arva-Ph.D-- Ph.D. degree 6/2006  
Tarek Abbas – Ph.D. degree 1/2004  
Angelika Brekman-Ph.D. degree 5/2011  
Ernest Boamah-Ph.D. degree 5/2010  
Agustin Chicas - Ph.D. degree 1/2001  
Valery Chavez- current Ph.D. student  
AnnMarie Gaglio- current Ph.D. student  
Chong Gao- Ph.D. degree 6/2019  
Tamara Gopen- Ph.D. degree 1/2005  
Sandy Hoffman Gamms- Ph.D .degree 5/2013  
Sandra Houser – Ph.D. degree 6/2003  
Nandini Kundu- Ph.D. degree 6/2017  
Rusia Lee- Ph.D. degree 6/2024  
Devon Lundine- Ph.D. degree 8/2021  
Nikita Meghani- current Ph.D. student  
Maria Patricia Molina - Ph.D. degree 6/2001  
Melissa Rosso-Ph.D. Ph.D. degree 10/2015  
Danielle Okoro-Ph.D. degree 5/2013  
David White-Ph.D.- Ph.D. degree 6/2005  
Gu Xiao - Ph.D. degree 1/2000

Katherine Renoso- graduated with the M.S.  
Tianhong Lu –graduated with the M.S.

**Undergraduate Students (BOLD=published with my group) –**

**480 lab research Undergraduate students Spring 2021-present:**

Tamar  
Nicole  
Nicky Chan  
Diana Katenov  
Pam Leybengrub-2021-2022 2 semesters of 480 and now in medical school  
Emily Chan- 2022-2023- now going for MPH  
Uska Naveed-2022  
Don-Gerard Conde (MARC 2020-2022)- now in Cornell graduate school  
Falande Alexandre (RISE 2020-2022)  
Dominique Forbes (RISE 2018-present)- now science teacher  
Alexandra Kern-2020-2021-now in medical shool  
Shuhong Jiang-2020-2021

Zafar Syed-2020-2021  
Nour Elshabassy-2020-2021-now in PA school  
Clara Freedman-2018-2020- now in medical school  
**480 lab research Undergraduate students Fall 2019:** Jinery Lora, Linda Yohannes, Shima Nikkah, Dion Denyko, Oneeb Tahir, Ashley Brown, Hajar Hamza.  
Soham Goshal (2017-2018) in school now for MD  
Ashley Brown (2017-2019)  
Jorge Canar (2017-2020)-now in graduate school  
Iffath Islam (2016-2018) **MS** in school now for MD  
Prima Manandhar (HHMI- 2013-2016) **MPH**  
Nabanita Hossain (2015-2017) in school now for MD  
Robert Gullery (2015-2018)  
**Jun Yeob Kim** (2013-2019)  
Josh Kogan (Leadership Alliance Summer 2012)  
Vincent Anguiano (MARC 2011-2013) **PhD**  
Renee Cotton (Leadership Alliance Summer 2010)  
Patricia Garcia (Leadership Alliance Summer 2009- Princeton) **PhD**  
Danielle Pasquel (Leadership Alliance Summer 2008- Einstein) **PhD**  
**Cindy Puente** 2006-2009 (MARC and HHMI- Sloan Kettering) **PhD**  
Mandeep Kaur 2007-2009 (MARC) **MD**  
Albana Thomaraj 2005-2008 **DPM**  
Aashish Jethra 2005-2006 (MBRS) -science career  
Steve Simpson Jr. 2004-2005 (MPh) **MPH**  
Sarwish Rafiq 2004-2005 (PhD Program) **PhD- now Professor at Emory**  
Elena Zvyagintseva 2004-2005  
**Danielle Okoro** 2004-2007 (MARC- CUNY Hunter PhD) **PhD**  
**Latoya Campbell** 2003-2004 (MARC- UPenn Graduate School) **PhD**  
Christina Medina (RCMI Summer Fellow 2001-Einstein PhD granted) **PhD-now STEM and student success administrator**  
Jackie Lopez: (RCMI Summer Fellow 1999 and 2000 MBRS 2000-2002)  
Lincoln Roland: B.S. 2000 (Howard Hughes Fellow)  
Fernando Hernandez: B.S. 2000 (MARC) **MD**  
Mark Lester (RCMI Summer Fellow 2000) **MD**  
Leonardo Vergare 1999  
Ayana Charleston (RCMI Summer Fellow 1999)  
DeMarco Smalls (RCMI Summer Fellow 1998)  
Quanjing Liu: B.S. 1998  
Jean-Patrick Parisien: B.S. (Howard Hughes Fellow 1997)

**Postdoctoral Fellows and Research Associates:**

Viola Ellison: (present)  
Gu Xiao: (present)  
Nataly Shtraizent: currently Scientist/Entrepreneur

Agustin Chicas: currently [Director of Biology/ Head of Translational Drug Discovery \(Boston\) at Monte Rosa Therapeutics](#)

Magali Olivier: currently Scientist at International Agency for Research on Cancer

Sergei Koshlatyi (MD Long Island Jewish)

### Teaching record

#### **Courses taught and designed at The Graduate Center**

**Fall 2009-present** *Seminar in Molecular, Cell and Developmental Biology Biology 79302(97084)*

#### **Courses taught and designed at Hunter College:**

**2015-present** Hunter College Undergraduate  
"Choreographing Genomics"  
**2014** Undergraduate Major Required Course/ Restructure Curriculum  
"Molecular Cell Biol:303"  
**2014** Hunter College Graduate/Undergraduate Seminar Course:  
"Cancer Genomics"  
**2005-2008** Hunter College Graduate/Undergraduate Seminar Course:  
"Genomics and the Human Race: Cancer and More"  
**1996-2013** Undergraduate Major Required Course  
"Molecular Genetics Biol:302" (course coordinator beginning in 1997, new integrated lecture laboratory implemented with CAREER award)  
Biology 602 is an integrated Graduate Molecular Genetics/ teaching methods course.  
Independent instructor course from 2004-2010  
**1995-2004** Hunter College Graduate/Undergraduate Seminar Course:  
"Damaged Genes in Tumor Cells"

#### **Students from "Damaged Genes" Seminar Awarded Best Research Paper in Hunter College Library Competition:**

1999 Yaelle Ehrenpreis 1<sup>st</sup> Place- Graduate Competition  
1998 Marco Domeniconi 2<sup>nd</sup> Place- Undergraduate (Paper accepted for Honors Journal)  
1997 Agustin Chicas 2<sup>nd</sup> Place- Graduate Competition  
**1995** Undergraduate Cell Biology  
**1994** Graduate Cell Biology, Ph.D. Program